Technology & Innovations
Lariat II Suture Delivery Device
by Steve S. Ryan, updated Oct. 2016
To address the increased risk of stroke, A-Fib patients are often put on anticoagulant drug therapy, such as warfarin. Because the Left Atrial Appendage (LAA) is the source of over 90% of A-Fib-related strokes, the Lariat II Suture, an occlusion device, can be used to close off the LAA, replacing the need for anticoagulants.
It is often used in cases where the patient cannot tolerate anticoagulants like Coumadin. (The Watchman device, another occlusion device, requires a patient be on anticoagulants for several months. See The Watchman™: Alternative to Blood Thinners.)
Placement of the Lariat Device
From the inside of the heart a balloon is placed inside the Left Atrial Appendage to expand it and make it accessible to the noose device which is inserted from the outside of the heart. The positioning balloon is withdrawn before the Lariat noose is closed around the base of the Left Atrial Appendage.
The noose completely closes off the Left Atrial Appendage which dies and is no longer electrically active. The Lariat II snare device has been approved by the FDA (Lariat II, SentreHeart, Inc., Palo Alto, CA).
A noose device to close off the Left Atrial Appendage is inserted from outside the heart, unlike for example the Watchman device which is inserted into the LAA from inside the heart.
The Lariat device was invented by Dr. William E. “Billy” Cohn, Director of Minimally Invasive Surgical Technology at the Texas Heart Institute at St. Luke’s Episcopal Hospital.
VIDEO: Closure of the Left Atrial Appendage Technique 2: The Lariat Procedure. Using doctor interviews and animated footage, explains the need for and use of the Lariat occlusion device.
For more about the Lariat, see Alert: Patients with Lariat Device for Left Atrial Appendage Closure.
Return to Index of Articles: Research and Innovations
Last updated: Wednesday, October 12, 2016